Gossamer Bio 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GB001 / Teijin, Gossamer Bio
2019-001682-33: GB001 in Adult Subjects with Chronic Rhinosinusitis

Not yet recruiting
2
100
RoW
GB001, Film-coated tablet
GB001, Inc., GB001, Inc.
Chronic Rhinosinusitis with or without Nasal Polyps, Chronic Rhinosinusitis, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT06429566: Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous Ulcers

Active, not recruiting
2
120
RoW
GB001 recombinant peptide spray low dose group、high dose group, GB001 recombinant peptide spray placebo
Zhejiang Echon Biopharm Limited
Healthy
12/23
07/26
NCT05125211: Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy Subjects

Active, not recruiting
1
91
RoW
GB001 recombinant peptide spray, Placebo
Zhejiang Echon Biopharm Limited
Healthy
11/22
05/26
HEATPAD, NCT06186505: Heat Therapy for Peripheral Arterial Disease

Not yet recruiting
N/A
40
NA
AirGlove, GB001
Norfolk and Norwich University Hospitals NHS Foundation Trust, GreenCross Medico Limited
Peripheral Arterial Disease, Intermittent Claudication, Critical Limb Ischemia
10/28
12/28
GB1275 / Gossamer Bio
2019-001879-37: Open-label, Dose Escalation Study of GB1275 Alone and in Combination with Anti-PD 1 Antibody in Patients with Advanced Solid Tumors or in Combination with Standard of Care with Patients with Metastatic Pancreatic Adenocarcinoma, Followed by a Dose Expansion of GB1275 with Standard of Care or in Combination with an Anti-PD-1 Antibody in Patients with Metastatic Solid Tumors

Not yet recruiting
1/2
242
Europe
GB1275, Pembrolizumab, GB1275, Pembrolizumab, Tablet, Solution for infusion, KEYTRUDA (Pembrolizumab)
GB006, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc., GB006, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc.
Phase 1: Advanced solid tumors, metastatic pancreatic adenocarcinomaPhase 2: Specified metastatic solid tumors, Phase 1: Advanced, abnormal mass of cancerous tissue and cancer of the pancreas that has spread to other parts of the bodyPhase 2: cells that break away from original solid tumor and form new tumors, Diseases [C] - Cancer [C04]
 
 
seralutinib (GB002) / Gossamer Bio
NCT06274801: Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Recruiting
3
300
Europe, Japan, US, RoW
Seralutinib, Gereic Dry Powder Inhaler
GB002, Inc.
Pulmonary Arterial Hypertension
12/26
12/26
NCT05934526: Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Active, not recruiting
3
350
Europe, Canada, Japan, US, RoW
Placebo, Seralutinib, Generic Dry Powder Inhaler
GB002, Inc.
Pulmonary Arterial Hypertension
09/25
10/25
2019-002669-37: Clinical Study of Inhaled GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Not yet recruiting
2
80
Europe
GB002 Capsules, GB002, Inhalation powder, hard capsule
GB002, Inc., GB002, Inc.
Pulmonary Arterial Hypertension (PAH), WHO Group 1 pulmonary arterial hypertension is associated with raised blood pressure in the pulmonary artery due to abnormalities in the small branches of the pulmonary artery, the arterioles., Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT04816604 / 2020-005169-15: Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Active, not recruiting
2
74
Europe, US, RoW
GB002 (seralutinib), Generic Dry Powder Inhaler
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Pulmonary Arterial Hypertension
12/27
12/27
2018-003093-27: Clinical Study of Inhaled GB002 for the Treatment of WHO Group I Pulmonary Arterial Hypertension (PAH)

Not yet recruiting
1/2
16
Europe
GB002 Capsules, GB002, Inhalation powder, hard capsule
GB002, Inc., GB002, Inc.
Pulmonary Arterial Hypertension (PAH), WHO Group 1 pulmonary arterial hypertension is associated with raised blood pressure in the pulmonary artery due to abnormalities in the small branches of the pulmonary artery, the arterioles, Diseases [C] - Cardiovascular Diseases [C14]
 
 
YKSW-GB002-R01, NCT06423261: Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy Subjects

Active, not recruiting
1
100
RoW
GB002 Recombinant Peptide Inhalation Solution, Placebo
Zhejiang Echon Biopharm Limited
Healthy
12/25
07/26
GB5121 / Gossamer Bio
STAR CNS, NCT05242146 / 2021-006234-39: GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

Terminated
1b/2
12
Europe, Canada, US, RoW
GB5121
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc., GB005, Inc.
CNS Lymphoma
05/23
05/23
2021-006234-39: A study of GB5121 in adults with cancer of the central nervous system that has reappeared or did not respond to prior therapy Un estudio de GB5121 en adultos con cáncer del sistema nervioso central que ha reaparecido o no ha respondido a la terapia anterior

Ongoing
1/2
143
Europe
GB5121, Capsule, soft
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc., GB005, Inc.
Relapsed/refractory primary or secondary central nervous system lymphoma or primary vitreoretinal lymphoma Linfoma primario o secundario del sistema nervioso central o linfoma vitreorretiniano primario recidivante/resistente al tratamiento, Cancer of the central nervous system Cáncer del sistema nervioso central, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
GB7208 / Gossamer Bio
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GB001 / Teijin, Gossamer Bio
2019-001682-33: GB001 in Adult Subjects with Chronic Rhinosinusitis

Not yet recruiting
2
100
RoW
GB001, Film-coated tablet
GB001, Inc., GB001, Inc.
Chronic Rhinosinusitis with or without Nasal Polyps, Chronic Rhinosinusitis, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT06429566: Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous Ulcers

Active, not recruiting
2
120
RoW
GB001 recombinant peptide spray low dose group、high dose group, GB001 recombinant peptide spray placebo
Zhejiang Echon Biopharm Limited
Healthy
12/23
07/26
NCT05125211: Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy Subjects

Active, not recruiting
1
91
RoW
GB001 recombinant peptide spray, Placebo
Zhejiang Echon Biopharm Limited
Healthy
11/22
05/26
HEATPAD, NCT06186505: Heat Therapy for Peripheral Arterial Disease

Not yet recruiting
N/A
40
NA
AirGlove, GB001
Norfolk and Norwich University Hospitals NHS Foundation Trust, GreenCross Medico Limited
Peripheral Arterial Disease, Intermittent Claudication, Critical Limb Ischemia
10/28
12/28
GB1275 / Gossamer Bio
2019-001879-37: Open-label, Dose Escalation Study of GB1275 Alone and in Combination with Anti-PD 1 Antibody in Patients with Advanced Solid Tumors or in Combination with Standard of Care with Patients with Metastatic Pancreatic Adenocarcinoma, Followed by a Dose Expansion of GB1275 with Standard of Care or in Combination with an Anti-PD-1 Antibody in Patients with Metastatic Solid Tumors

Not yet recruiting
1/2
242
Europe
GB1275, Pembrolizumab, GB1275, Pembrolizumab, Tablet, Solution for infusion, KEYTRUDA (Pembrolizumab)
GB006, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc., GB006, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc.
Phase 1: Advanced solid tumors, metastatic pancreatic adenocarcinomaPhase 2: Specified metastatic solid tumors, Phase 1: Advanced, abnormal mass of cancerous tissue and cancer of the pancreas that has spread to other parts of the bodyPhase 2: cells that break away from original solid tumor and form new tumors, Diseases [C] - Cancer [C04]
 
 
seralutinib (GB002) / Gossamer Bio
NCT06274801: Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Recruiting
3
300
Europe, Japan, US, RoW
Seralutinib, Gereic Dry Powder Inhaler
GB002, Inc.
Pulmonary Arterial Hypertension
12/26
12/26
NCT05934526: Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Active, not recruiting
3
350
Europe, Canada, Japan, US, RoW
Placebo, Seralutinib, Generic Dry Powder Inhaler
GB002, Inc.
Pulmonary Arterial Hypertension
09/25
10/25
2019-002669-37: Clinical Study of Inhaled GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Not yet recruiting
2
80
Europe
GB002 Capsules, GB002, Inhalation powder, hard capsule
GB002, Inc., GB002, Inc.
Pulmonary Arterial Hypertension (PAH), WHO Group 1 pulmonary arterial hypertension is associated with raised blood pressure in the pulmonary artery due to abnormalities in the small branches of the pulmonary artery, the arterioles., Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT04816604 / 2020-005169-15: Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Active, not recruiting
2
74
Europe, US, RoW
GB002 (seralutinib), Generic Dry Powder Inhaler
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Pulmonary Arterial Hypertension
12/27
12/27
2018-003093-27: Clinical Study of Inhaled GB002 for the Treatment of WHO Group I Pulmonary Arterial Hypertension (PAH)

Not yet recruiting
1/2
16
Europe
GB002 Capsules, GB002, Inhalation powder, hard capsule
GB002, Inc., GB002, Inc.
Pulmonary Arterial Hypertension (PAH), WHO Group 1 pulmonary arterial hypertension is associated with raised blood pressure in the pulmonary artery due to abnormalities in the small branches of the pulmonary artery, the arterioles, Diseases [C] - Cardiovascular Diseases [C14]
 
 
YKSW-GB002-R01, NCT06423261: Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy Subjects

Active, not recruiting
1
100
RoW
GB002 Recombinant Peptide Inhalation Solution, Placebo
Zhejiang Echon Biopharm Limited
Healthy
12/25
07/26
GB5121 / Gossamer Bio
STAR CNS, NCT05242146 / 2021-006234-39: GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

Terminated
1b/2
12
Europe, Canada, US, RoW
GB5121
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc., GB005, Inc.
CNS Lymphoma
05/23
05/23
2021-006234-39: A study of GB5121 in adults with cancer of the central nervous system that has reappeared or did not respond to prior therapy Un estudio de GB5121 en adultos con cáncer del sistema nervioso central que ha reaparecido o no ha respondido a la terapia anterior

Ongoing
1/2
143
Europe
GB5121, Capsule, soft
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc., GB005, Inc.
Relapsed/refractory primary or secondary central nervous system lymphoma or primary vitreoretinal lymphoma Linfoma primario o secundario del sistema nervioso central o linfoma vitreorretiniano primario recidivante/resistente al tratamiento, Cancer of the central nervous system Cáncer del sistema nervioso central, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
GB7208 / Gossamer Bio
No trials found

Download Options